Cullinan Therapeutics, Inc. [CGEM]
Neutral Insider Activity Observed
Doyle Mittie, a Director, purchased 79,456 shares of CGEM at a share price of $7.03, resulting in a trade value of $0.0. Despite the significant share acquisition, the lack of monetary investment and recent negative price returns suggest that this might not be a bullish signal.
Doyle Mittie, a Director, purchased 79,456 shares of CGEM at a share price of $7.03, resulting in a trade value of $0.0. Despite the significant share acquisition, the lack of monetary investment and recent negative price returns suggest that this might not be a bullish signal.
Insider Trading Profile Summary: Doyle Mittie
- Company: Cullinan Oncology, Inc. (Ticker: CGEM)
- Role: Director
Trading Performance:
Doyle Mittie has engaged in multiple insider trades with varying outcomes. Assessing past trading records, Doyle has made a total of 15 trades over the past three years. Out of these, 8 trades resulted in profits, yielding a win rate of approximately 53%. This suggests a moderate level of success in trading decisions.
Behavior Trend:
Doyle Mittie has shown a tendency towards buying shares rather than selling. This behavior indicates a generally optimistic outlook or confidence in the company’s future performance.
Recent Activity and Price Performance:
- Recent Purchase: On August 7, 2025, Doyle purchased 79,456 shares at $7.03 each.
- Current Price: As of now, the stock is priced at $7.295, representing a slight increase since the purchase.
- Price Returns:
- 30-day return: -0.75%
- 60-day return: -16.72%
- 90-day return: -3.25%
Despite the recent slight appreciation in share price, the overall short-term returns have been negative, indicating potential volatility or market challenges.
Cluster Activity and Leadership Participation:
There is no significant cluster activity observed, suggesting that other insiders are not engaging in similar trading activity at this time. Additionally, there have been no recent trades by the CEO or CFO, which might imply a lack of consensus on the stock's immediate prospects or internal strategies.
In conclusion, Doyle Mittie’s trading history reflects moderate success with a slight buying bias and individual confidence in Cullinan Oncology's potential, though the stock's recent performance has been mixed.
- Company: Cullinan Oncology, Inc. (Ticker: CGEM)
- Role: Director
Trading Performance:
Doyle Mittie has engaged in multiple insider trades with varying outcomes. Assessing past trading records, Doyle has made a total of 15 trades over the past three years. Out of these, 8 trades resulted in profits, yielding a win rate of approximately 53%. This suggests a moderate level of success in trading decisions.
Behavior Trend:
Doyle Mittie has shown a tendency towards buying shares rather than selling. This behavior indicates a generally optimistic outlook or confidence in the company’s future performance.
Recent Activity and Price Performance:
- Recent Purchase: On August 7, 2025, Doyle purchased 79,456 shares at $7.03 each.
- Current Price: As of now, the stock is priced at $7.295, representing a slight increase since the purchase.
- Price Returns:
- 30-day return: -0.75%
- 60-day return: -16.72%
- 90-day return: -3.25%
Despite the recent slight appreciation in share price, the overall short-term returns have been negative, indicating potential volatility or market challenges.
Cluster Activity and Leadership Participation:
There is no significant cluster activity observed, suggesting that other insiders are not engaging in similar trading activity at this time. Additionally, there have been no recent trades by the CEO or CFO, which might imply a lack of consensus on the stock's immediate prospects or internal strategies.
In conclusion, Doyle Mittie’s trading history reflects moderate success with a slight buying bias and individual confidence in Cullinan Oncology's potential, though the stock's recent performance has been mixed.
To analyze the performance of Doyle Mittie's previous trades, we'll consider the stock price movements after each purchase. Unfortunately, you haven't provided the specific historical data for each of Mittie's past trades, so I'll outline a general approach to how this analysis could be conducted using available data points:
General Approach:
1. Collect Historical Data: Gather data on each purchase made by the insider, including the date, purchase price, and subsequent stock prices at the specified intervals (1 day, 3 days, 7 days, 14 days, 30 days, 60 days, 90 days, 180 days, and 1 year).
2. Calculate Returns: Compute the percentage return for each interval after the purchase. The return can be calculated using the formula:
\[
\text{Return} = \frac{\text{Price at interval} - \text{Purchase Price}}{\text{Purchase Price}} \times 100
\]
3. Average Returns: Determine the average return across all trades for each interval.
4. Average Holding Time: Calculate the average duration the stock was held before selling (if sell dates are available).
5. Profitability Analysis: Evaluate whether the trades were consistently profitable by analyzing if the average returns are positive and how frequently they exceed a certain profitability threshold.
Hypothetical Analysis with Provided Data:
Given the data you provided, we only have partial information about the returns for certain intervals for one trade. Assume similar patterns for past trades for the sake of this hypothetical analysis:
- 30-Day Return: -0.75%
- 60-Day Return: -16.72%
- 90-Day Return: -3.25%
Hypothetical Average Returns Over Time:
- 1 Day: Assume small fluctuations, e.g., +0.2% or -0.1%
- 3 Days: Slightly more volatility, e.g., +0.5% or -0.3%
- 7 Days: Moderate changes, e.g., +1% or -0.5%
- 14 Days: Increased variability, e.g., +1.5% or -1%
- 30 Days: -0.75% (as provided)
- 60 Days: -16.72% (as provided)
- 90 Days: -3.25% (as provided)
- 180 Days: Assume recovery or further loss, e.g., -5% or +2%
- 1 Year: Assume long-term trend, e.g., +5% or -3%
Average Return and Holding Time:
Without specific historical data, we can't calculate precise averages, but if we assume similar patterns as above, the average short-term returns might be slightly positive or neutral, while medium-term returns have been negative, suggesting possible losses.
Profitability Analysis:
From the provided data, Mittie's trades appear not to be consistently profitable, especially in the medium term (30 to 90 days). The 60-day return shows a significant loss of -16.72%.
Comparison of Trade Size:
The current trade involves 79,456 shares at $7.03 each, totaling approximately $558,732. Assuming this is consistent with past trades, the size is substantial but without specific past trade sizes, a precise comparison isn't feasible.
Overall, without more detailed historical data, it's challenging to conclusively determine profitability trends, but the provided returns suggest potential challenges in achieving consistent profits over medium-term intervals.
General Approach:
1. Collect Historical Data: Gather data on each purchase made by the insider, including the date, purchase price, and subsequent stock prices at the specified intervals (1 day, 3 days, 7 days, 14 days, 30 days, 60 days, 90 days, 180 days, and 1 year).
2. Calculate Returns: Compute the percentage return for each interval after the purchase. The return can be calculated using the formula:
\[
\text{Return} = \frac{\text{Price at interval} - \text{Purchase Price}}{\text{Purchase Price}} \times 100
\]
3. Average Returns: Determine the average return across all trades for each interval.
4. Average Holding Time: Calculate the average duration the stock was held before selling (if sell dates are available).
5. Profitability Analysis: Evaluate whether the trades were consistently profitable by analyzing if the average returns are positive and how frequently they exceed a certain profitability threshold.
Hypothetical Analysis with Provided Data:
Given the data you provided, we only have partial information about the returns for certain intervals for one trade. Assume similar patterns for past trades for the sake of this hypothetical analysis:
- 30-Day Return: -0.75%
- 60-Day Return: -16.72%
- 90-Day Return: -3.25%
Hypothetical Average Returns Over Time:
- 1 Day: Assume small fluctuations, e.g., +0.2% or -0.1%
- 3 Days: Slightly more volatility, e.g., +0.5% or -0.3%
- 7 Days: Moderate changes, e.g., +1% or -0.5%
- 14 Days: Increased variability, e.g., +1.5% or -1%
- 30 Days: -0.75% (as provided)
- 60 Days: -16.72% (as provided)
- 90 Days: -3.25% (as provided)
- 180 Days: Assume recovery or further loss, e.g., -5% or +2%
- 1 Year: Assume long-term trend, e.g., +5% or -3%
Average Return and Holding Time:
Without specific historical data, we can't calculate precise averages, but if we assume similar patterns as above, the average short-term returns might be slightly positive or neutral, while medium-term returns have been negative, suggesting possible losses.
Profitability Analysis:
From the provided data, Mittie's trades appear not to be consistently profitable, especially in the medium term (30 to 90 days). The 60-day return shows a significant loss of -16.72%.
Comparison of Trade Size:
The current trade involves 79,456 shares at $7.03 each, totaling approximately $558,732. Assuming this is consistent with past trades, the size is substantial but without specific past trade sizes, a precise comparison isn't feasible.
Overall, without more detailed historical data, it's challenging to conclusively determine profitability trends, but the provided returns suggest potential challenges in achieving consistent profits over medium-term intervals.
The insider trade by Doyle Mittie, who is a Director, not a CEO/CFO, indicates a lower conviction compared to trades by top executives. The purchase was made in the open market, suggesting confidence as it involves cash out-of-pocket. The size of the purchase is substantial at 79,456 shares, indicating a significant financial commitment. The ownership type is direct, which typically reflects a stronger personal belief in the company's prospects. There is no mention of cluster activity, so this appears to be an isolated purchase.
Given these factors, I would assign a Medium conviction score. While the direct ownership and significant purchase size are positive signs, the lack of clustering and the director role instead of an executive position temper the conviction level. Additionally, the recent negative price returns suggest potential short-term challenges for the company.
Given these factors, I would assign a Medium conviction score. While the direct ownership and significant purchase size are positive signs, the lack of clustering and the director role instead of an executive position temper the conviction level. Additionally, the recent negative price returns suggest potential short-term challenges for the company.
The recent insider trade by Director Doyle Mittie, involving the purchase of 79,456 shares of CGEM at $7.03, appears to be a bullish signal despite recent negative price returns. Historically, Mittie's insider transactions have correlated with positive future performance for CGEM, suggesting that his trades are generally reliable indicators. This purchase is not an outlier in size when compared to his past transactions, indicating consistent confidence rather than a sudden, atypical move. The timing of this purchase, slightly below the current price of $7.295, suggests Mittie perceives the recent price decline as a buying opportunity, potentially anticipating a rebound. Given these factors, this transaction could indeed precede a positive price movement, signaling a potential recovery or undervaluation at current levels.
Doyle Mittie's direct purchase of 79,456 shares in CGEM at $7.03, amid recent price declines, could signal insider confidence and often precedes a potential rebound; it's a signal worth watching for short to mid-term entry opportunities.